# Efficacy and Safety of Immunoglobulin Associated With Rituximab Versus Rituximab Alone in Childhood-Onset Steroid-dependent Nephrotic Syndrome

> **NCT03560011** · PHASE2,PHASE3 · SUSPENDED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 90 (estimated)

## Conditions studied

- Steroid-Dependent Nephrotic Syndrome

## Interventions

- **DRUG:** immunoglobulin IV

## Key facts

- **NCT ID:** NCT03560011
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2019-04-03
- **Primary completion:** 2021-01-07
- **Final completion:** 2022-11-04
- **Target enrollment:** 90 (ESTIMATED)
- **Why stopped:** Decision of Data Safety Monitoring Board
- **Last updated:** 2021-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03560011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03560011, "Efficacy and Safety of Immunoglobulin Associated With Rituximab Versus Rituximab Alone in Childhood-Onset Steroid-dependent Nephrotic Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03560011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*